{"id":637851,"date":"2023-02-10T19:54:02","date_gmt":"2023-02-10T19:54:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=637851"},"modified":"2023-02-10T19:54:02","modified_gmt":"2023-02-10T19:54:02","slug":"the-acute-kidney-injury-market-to-grow-positively-at-a-significant-cagr-during-the-study-period-20192032-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-acute-kidney-injury-market-to-grow-positively-at-a-significant-cagr-during-the-study-period-20192032-estimates-delveinsight_637851.html","title":{"rendered":"The Acute Kidney Injury Market to Grow Positively at a significant CAGR During the Study Period (2019-2032), estimates DelveInsight"},"content":{"rendered":"
\"The<\/a><\/div>\n

DelveInsight’s “Acute Kidney Injury Market Insight, Epidemiology and Market Forecast 2032<\/a>”<\/strong> report provides current treatment practices, emerging drugs, Acute Kidney Injury market share of the individual therapies, current and forecasted Acute Kidney Injury market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Kidney Injury therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Kidney Injury market.<\/p>\n

 <\/p>\n

Acute Kidney Injury Overview<\/strong><\/p>\n

Acute Kidney Injury is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. Signs and symptoms of AKI includes, nausea, vomiting, weakness, dizziness and, pain in lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.<\/p>\n

 <\/p>\n

Acute Kidney Injury Epidemiological Insights<\/strong><\/p>\n

The United States contributed to the largest incident population of Acute Kidney Injury, accounting for ~ 34% of the 7MM in 2021, asserts DelveInsight.<\/p>\n

 <\/p>\n

Acute Kidney Injury Treatment Market <\/a><\/strong><\/p>\n

Acute Kidney Injury pipeline with a novel mechanism of action and increasing incidence are major market drivers of AKI market. Additionally, the AKI pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action.<\/p>\n

Currently, there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of AKI is mainly dominated by the use of Renal Replacement Therapy (RRT) and off-label drugs, which include various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).<\/p>\n

 <\/p>\n

Promising Therapies in the Acute Kidney Injury Pipeline<\/a><\/strong><\/p>\n